4.5 Article

Use of Latent Variable Modeling to Delineate Psychiatric and Cognitive Profiles in Parkinson Disease

期刊

AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
卷 17, 期 11, 页码 986-995

出版社

ELSEVIER SCIENCE INC
DOI: 10.1097/JGP.0b013e3181b215ec

关键词

Parkinson disease; neuropsychology; psychiatry; cognition; depression

资金

  1. National Institute of Mental Health (NIMH) [067894]

向作者/读者索取更多资源

Objectives: A range of psychiatric symptoms and cognitive deficits occur in Parkinson disease (PD), and symptom overlap and comorbidity complicate the classification of nonmotor symptoms. The objective of this study was to use analytic-based approaches to classify psychiatric and cognitive symptoms in PD. Design: Cross-sectional evaluation of a convenience sample of patients in specialty care. Setting: Two outpatient movement disorders centers at the University of Pennsylvania and Philadelphia Veterans Affairs Medical Center. Participants: One hundred seventy-seven patients with mild-moderate idiopathic PD and without significant global cognitive impairment. Measurements: Subjects were assessed with an extensive psychiatric, neuropsychological, and neurological battery. Latent class analysis (LCA) was used to statistically delineate group-level symptom profiles across measures of psychiatric and cognitive functioning. Predictors of class membership were also examined. Results: Results from the LCA indicated that a four-class solution best fit the data. The 32.3% of the sample had good psychiatric and normal cognitive functioning, 17.5% had significant psychiatric comorbidity but normal cognition, 26.0% had few psychiatric symptoms but had poorer cognitive functioning across a range of cognitive domains, and 24.3% had both significant psychiatric comorbidity and poorer cognitive functioning. Age, disease severity, and medication use predicted class membership. Conclusions: LCA delineates four classes of patients in mild-moderate PD, three of which experience significant nonmotor impairments and comprise over two thirds of patients. Neuropsychiatric symptoms and cognitive deficits follow distinct patterns in PD, and further study is needed to determine whether these classes are generalizable, stable, predict function, quality of life, and long-term outcomes and are amenable to treatment at a class level. (Am J Geriatr Psychiatry 2009; 17:986-995)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Genetic prediction of impulse control disorders in Parkinson's disease

Daniel Weintraub, Marijan Posavi, Pierre Fontanillas, Thomas F. Tropea, Eugenia Mamikonyan, Eunran Suh, John Q. Trojanowski, Paul Cannon, Vivianna M. Van Deerlin, Alice S. Chen-Plotkin

Summary: In this study, a clinico-genetic predictor called ICD-RS was developed to identify the risk of impulse control disorder (ICD) in Parkinson's disease (PD) patients. The ICD-RS demonstrated a high accuracy in predicting ICD risk and can be used to guide pharmacogenetic approaches to PD medication selection.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2022)

Article Clinical Neurology

Characterization of Non-Motor Fluctuations Using the Movement Disorder Society Non-Motor Rating Scale

Daniel Johannes van Wamelen, Silvia Rota, Anette Schrag, Alexandra Rizos, Pablo Martinez-Martin, Daniel Weintraub, Kallol Ray Chaudhuri

Summary: This study examines non-motor fluctuations in Parkinson's disease patients, finding that the prevalence of NMF increases with disease duration in a pattern different from motor fluctuations. Additionally, NMF can occur in Parkinson's disease patients without dyskinesia, and the severity of NMF increases most during the 2-5 years after diagnosis.

MOVEMENT DISORDERS CLINICAL PRACTICE (2022)

Article Clinical Neurology

Digital Histological Study of Neocortical Grey and White Matter Tau Burden Across Tauopathies

David G. Coughlin, Annie Hiniker, Claire Peterson, Yongya Kim, Sanaz Arezoumandan, Lucia Giannini, Donald Pizzo, Daniel Weintraub, Andrew Siderowf, Irene Litvan, Robert A. Rissman, Douglas Galasko, Lawrence Hansen, John Q. Trojanowski, Edward Lee, Murray Grossman, David Irwin

Summary: This study used digital image analysis techniques to evaluate the distribution of tau pathology in different diseases and found that AD and LBD+tau had the highest tau burden in the superior temporal cortex. In addition, 4R-tauopathies had relatively higher white matter tau burden and there was a positive correlation between grey and white matter tau.

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2022)

Article Clinical Neurology

Plasma phosphorylated tau181 predicts cognitive and functional decline

Thomas F. Tropea, Teresa Waligorska, Sharon X. Xie, Ilya M. Nasrallah, Katheryn A. Q. Cousins, John Q. Trojanowski, Murray Grossman, David J. Irwin, Daniel Weintraub, Edward B. Lee, David A. Wolk, Alice S. Chen-Plotkin, Leslie M. Shaw

Summary: The objective of this study was to determine if plasma tau phosphorylated at threonine 181 (p-tau181) can distinguish Alzheimer's disease (AD) from normal cognition (NC) in adults, predict cognitive and functional decline, and validate findings in an external cohort. The results showed that plasma p-tau181 can accurately differentiate AD pathology from NC, and higher levels of p-tau181 are associated with faster cognitive and functional decline.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Article Clinical Neurology

Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated

John L. Robinson, Sharon X. Xie, Daniel R. Baer, EunRan Suh, Vivianna M. Van Deerlin, Nicholas J. Loh, David J. Irwin, Corey T. McMillan, David A. Wolk, Alice Chen-Plotkin, Daniel Weintraub, Theresa Schuck, Virginia M. Y. Lee, John Q. Trojanowski, Edward B. Lee

Summary: In this retrospective study, the incidence of 10 pathologies in neurodegenerative disease (ND) and normal aging was examined, with up to seven pathologies observed concurrently resulting in 161 different combinations. The presence of multiple additive pathologies was associated with factors such as longer disease duration, clinical dementia, older age, and APOE e4 status.
Article Clinical Neurology

Channeling of New Neuropsychiatric Drugs-Impact on Safety and Effectiveness Studies

Danielle S. Abraham, Thanh Phuong Pham Nguyen, Leah J. Blank, Dylan Thibault, Shelly L. Gray, Sean Hennessy, Charles E. Leonard, Daniel Weintraub, Allison W. Willis

Summary: This study examined the differential prescribing patterns between new and established treatments for common neurological conditions. Using data from a national sample of US commercially insured adults from 2005-2019, the study compared new users of recently approved medications for three conditions: diabetic peripheral neuropathy, Parkinson disease psychosis, and epilepsy. The results showed that newer medications were more frequently prescribed to individuals with prior treatment, suggesting potential bias in comparative effectiveness and safety studies. The study emphasizes the importance of reporting propensity score non-overlap in comparative studies involving newer medications and suggests methodological approaches to address channeling bias.

NEUROTHERAPEUTICS (2023)

Article Clinical Neurology

Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease

Katheryn A. Q. Cousins, David J. Irwin, Alice Chen-Plotkin, Leslie M. Shaw, Sanaz Arezoumandan, Edward B. Lee, David A. Wolk, Daniel Weintraub, Meredith Spindler, Andres Deik, Murray Grossman, Thomas F. Tropea

Summary: This study found that plasma GFAP may be sensitive to concomitant AD pathology in LBSD, especially accumulation of beta-amyloid plaques.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Article Neurosciences

LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts

Kalpana M. Merchant, Tanya Simuni, Janel Fedler, Chelsea Caspell-Garcia, Michael Brumm, Kelly N. H. Nudelman, Elizabeth Tengstrandt, Frank Hsieh, Roy N. Alcalay, Christopher Coffey, Lana Chahine, Tatiana Foroud, Andrew Singleton, Daniel Weintraub, Samantha Hutten, Todd Sherer, Brit Mollenhauer, Andrew Siderowf, Caroline Tanner, Ken Marek

Summary: We quantified concentrations of three isoforms of BMP in different cohorts of Parkinson's disease patients and found that LRRK2 and GBA1 gene mutations were associated with elevated BMP levels. However, BMP is not a prognostic or disease progression biomarker.

NPJ PARKINSONS DISEASE (2023)

Article Clinical Neurology

Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory Study

Daniel Weintraub, Marina Picillo, Hyunkeun Ryan Cho, Chelsea Caspell-Garcia, Cornelis Blauwendraat, Ethan G. Brown, Lana M. Chahine, Christopher S. Coffey, Roseanne D. Dobkin, Tatiana Foroud, Doug Galasko, Karl Kieburtz, Kenneth Marek, Kalpana Merchant, Brit Mollenhauer, Kathleen L. Poston, Tanya Simuni, Andrew Siderowf, Andrew Singleton, John Seibyl, Caroline M. Tanner

Summary: This study used data from a multi-site, international, prospective cohort study to investigate the impact of dopamine system-related biomarkers on cognitive impairment in Parkinson's disease. The results showed that alterations in the dopamine system were associated with the development of cognitive impairment in Parkinson's disease. If confirmed causative, these findings suggest that the dopamine system is instrumental to cognitive health status throughout the disease course.

MOVEMENT DISORDERS CLINICAL PRACTICE (2023)

Article Clinical Neurology

Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial

Hubert H. Fernandez, Daniel Weintraub, Eric Macklin, Irene Litvan, Michael A. Schwarzschild, Jamie Eberling, Aleksandar Videnovic, Christopher J. Kenney

Summary: In patients with Parkinson disease dementia (PDD), SYN120 did not improve cognition significantly but showed potential benefits in cognitive activities of daily living and apathy.

PARKINSONISM & RELATED DISORDERS (2023)

Article Clinical Neurology

Potentially inappropriate medications in older adults with Parkinson disease before and after hospitalization for injury

Thanh Phuong Pham Nguyen, Shelly L. Gray, Craig W. Newcomb, Qing Liu, Ali G. Hamedani, Daniel Weintraub, Sean Hennessy, Allison W. Willis

Summary: This study found that there were no significant differences in medication prescriptions between Parkinson disease (PD) patients hospitalized for serious injury and those hospitalized for other reasons, indicating a missed opportunity to deprescribe high-risk medications during care transitions.

PARKINSONISM & RELATED DISORDERS (2023)

Article Clinical Neurology

The Self-Administered Screening Questionnaire for Parkinson's Disease-Associated Psychosis (SASPAP)

Vindhya Koneru, Alberto J. Espay, Allan J. Cole, Daniel Weintraub, Kathleen Crist, Maria B. Pascual, William G. Ondo

MOVEMENT DISORDERS (2023)

Meeting Abstract Clinical Neurology

Human-in-the-Loop Machine Learning Curation of Problems That Bother Parkinson Disease Patients

Connie Marras, Lakshmi Arbatti, Amy Amara, Karen Anderson, Claire Bale, Lana Chahine, Shirley Eberly, Abhishek Hosamath, Daniel Kinel, Sneha Mantri, Soania Mathur, David Oakes, Jennifer Purks, Daniel Weintraub, Ira Shoulson

ANNALS OF NEUROLOGY (2022)

暂无数据